For the Culture By The Culture
Ohio rewrites its legalization law before it even starts, Wisconsin offers fake reform, and Massachusetts keeps spinning its regulatory wheels. The FDA pretends to act on CBD while the European Union adds new walls around its market. Reefer Report Card Vol. 20 grades another week of confusion, contradiction, and missed opportunities in global cannabis reform.
In a bizarre twist of bureaucratic brilliance, the DEA has reclassified marijuana as a leafy green vegetable—officially adding it to the American food pyramid. From salad bowls to school lunches, the War on Drugs just got edible. Satirical? Yes. Unbelievable? Barely.
The DEA is delaying the rescheduling of marijuana from Schedule I, despite overwhelming scientific support and recommendations from health authorities. This stalling harms the cannabis industry, patients, and communities affected by marijuana criminalization. Political influences from big pharmaceutical companies contribute to this resistance, prolonging the adverse effects of current drug policies.
The DEA’s delay in rescheduling cannabis is just a temporary hurdle for an industry and movement that refuses to be slowed down. Cannabis was once part of the counter-culture, now it is the culture. The future of cannabis is bright, and nothing is going to stop it
Reclassifying cannabis to Schedule III could revolutionize the medical cannabis landscape and provide much-needed tax relief for businesses. Discover the potential impacts and the next steps for cannabis reform in our latest article
Explore the significant leap in medical cannabis as the FDA approves CannRelief, a new CBD-based drug for chronic pain, promising a safer alternative to opioids. Image: A visually appealing photograph of a CannRelief pill bottle beside a cannabis leaf, symbolizing the connection between natural cannabis and medical innovation
